Prof. Dr. med. Felix JF Herth

He graduated from the University of Freiburg, Germany and received his training in Internal Medicine and Pneumology in Karlsruhe, Heidelberg and Boston.  Since 2004 he is the Head of the Department of Pneumology and since 2015 CEO and CMO of Thoraxklinik, University of Heidelberg, Heidelberg

His research interests include interventional pneumology, end-stage COPD and phenotyping of COPD. The team at Thoraxklinik is one of the world’s leading centers for the development of new minimal invasive endoscopic techniques, and together with the partners within the DZL his team initiated several trials on phenotyping of COPD for endoscopic lung volume reduction.

He is the Editor-in-Chief of Respiration and has served on many major committees, including the European Respiratory Society (ERS), the American College of Chest Physicians (ACCP) and the German Society of Pneumology (DGP). In 2012 he was President of the European Association for Bronchology and Interventional Pulmonology (EABIP). For his work he received numerous awards, including a Research Award from DGP and several Awards from ERS.

• Interventional Pulmonology
• COPD
• Rare Lung Disease

Chronic Obstructive Pulmonary Disease

1. Safety and Adverse Events after Targeted Lung Denervation for Symptomatic Moderate to Severe Chronic Obstructive Pulmonary Disease (AIRFLOW). A Multicenter Randomized Controlled Clinical Trial.  Slebos DJ, Shah PL, Herth FJF, Pison C, Schumann C, Hübner RH, Bonta PI, Kessler R, Gesierich W, Darwiche K, Lamprecht B, Perez T, Skowasch D, Deslee G, Marceau A, Sciurba FC, Gosens R, Hartman JE, Srikanthan K, Duller M, Valipour A; AIRFLOW-2 Study Group. Am J Respir Crit Care Med. 2019 Dec 15;200(12):1477-1486
2. Thermal vapour ablation to reduce segmental volume in patients with severe emphysema: STEP-UP 12 month results.  Shah PL, Gompelmann D, Valipour A, McNulty WH, Eberhardt R, Grah C, Egan J, Ficker JH, Wagner M, Witt C, Liebers U, Hopkins P, Gesierich W, Phillips M, Stanzel F, Petermann C, Strange C, Snell G, Herth FJF. Lancet Respir Med. 2016 Sep;4(9):e44-e45.
3. Segmental volume reduction using thermal vapour ablation in patients with severe emphysema: 6-month results of the multicentre, parallel-group, open-label, randomised controlled trial.  Herth FJ, Valipour A, Shah PL, Eberhardt R, Grah C, Egan J, Ficker JH, Wagner M, Witt C, Liebers U, Hopkins P, Gesierich W, Phillips M, Stanzel F, McNulty WH, Petermann C, Snell G, Gompelmann D. Lancet Respir Med. 2016 Mar;4(3):185-93. doi: 10.1016/S2213-2600(16)00045-X
4. Bronchoscopic transparenchymal nodule access (BTPNA): first in human trial of a novel procedure for sampling solitary pulmonary nodules.  Herth FJ, Eberhardt R, Sterman D, Silvestri GA, Hoffmann H, Shah PL. Thorax. 2015 Apr;70(4):326-32. doi: 10.1136/thoraxjnl-2014-206211
5. Radiological and clinical outcomes of using Chartis™ to plan endobronchial valve treatment.  Herth FJ, Eberhardt R, Gompelmann D, Ficker JH, Wagner M, Ek L, Schmidt B, Slebos DJ.Eur Respir J. 2013 Feb;41(2):302-8.

PubMed Link